Member Info for Retireby40

I have to say it’s pretty bad that we are below the raise of 3 years ago and we are suggesting 20p (albeit a 50% increase) in the summer will be good news. That’ll still need another 50% increase to get to the last discounted raise price.

No cash position in the last update was telling. They raised only in June and said EBITDA positive H2 so what have they done with it?

I’m not selling any more or indeed buying but GB needs to start delivering. I suspect they’re burning a lot more cash than planned (as per) and they need to get a grip as although the recent agreement can work if they generate cash and keep up to date on loans but it can easily go pear shaped.

I’m nervous without the China Resources deal. Something seems iffy to me but will see.

1) agreed
2) true but given the large uptick in cases it’ll be a priority
3) Data is reviewed as they go along so with sufficient numbers the timescale will be shorter (we also have a lot of safety data etc)

The Trotsky, I couldn’t agree more. The lack of news on cash position was as poor as rude. Unprofessional and they look unscrupulous. I still hold a decent number here but GB tells halve-truths. He needs to start reporting more transparently and professionally. They should introduce KPIs for each division and start to behave like a medium sized PLC not a tin pot minnow.

GB still running this like a small family business. Moan over.

But it was paused anyway as we needed a new trial design So this isn’t a surprise. Sadly covid kicking off again and hospitalisations/severe covid and death on the up so Sng001 needed as much as ever.

Sprinter results will come out when ready as it’s material and they will also look at activ-2 data is relation to sprinter too.

Surely we should be one of the favourites to win that?! I suppose sponsoring just in case we don’t!

T Rat it’s good they are on our radar but I’m surprised the last few RNSs don’t mention the US. Do we have any sales people driving MWG real-time monitoring in the US as the last few RNSs mention China, India, Middle East and Europe but no US?

Good to see we’re sponsoring the event but I would’ve expected some tangible traction before now ie we’re in testing as we are in UK and China.

Anyway, hopefully some tangible positive news soon.

I may well indeed thanks.

Gwoods a bitter ex-employee. Well here is as recent example -

A new peer-reviewed paper highlighting the use of Modern Water's MicroTrace PDV Series trace metal analyzer to detect and characterize arsenic in water was published in Environmental Science and Pollution Research. The work allowed the selection of the optimal arsenic treatment option The MicroTrace PDV is fully portable and capable of analyzing 24 different metals to the parts per billion level, - offering precise results in a matter of minutes. You can read the paper by clicking on the link below. Learn more about the MicroTrace PDV trace metals analyzer at:

https://lnkd.in/eWkdtuS

The equipment has been peer reviewed and is best in class.

I suspect a few will sign off on the wording and I suspect it’s the same every time as the RNSs have been mediocre to poor for a long time. The typos we used to get were bad enough but the vagueness has been an ongoing feature.

I hope the recent surge in covid cases in China means they wanna sign the deal and have the traditional face to face bit at a later date. Approaching a year. We need something solid like that and Any more wishy washy RNSs and we’ll go even lower.

Now that is Bull****. MWG has superb equipment and moving to that business model makes absolute sense for both parties.

What is frustrating is every time GB releases an RNS the share price falls which tells you they are crap. Poorly written and pose more questions than answers. I mean the ‘explanation moves from £ to $, it’s so amateur. They should’ve have said £5m in orders of which £3.3m will be realised FY22 and the remainder will be billed monthly in the subsequent 4 years due to blah blah.

*Serviced Lease explanation: Of the GBP5m production orders, 27 Microtox CTM units with a sales value of $1.08m are to be installed on a 60 month serviced lease with monitoring and consumables at $40,000 per month. This is $480,000 over the first 12 months from installation date resulting in $2.4m over 5-years.

No they’ve sold £5m worth of kit but circa £3m will fall into this year as 4 years lease and maintenance at circa 40k/month for 4 years which is around £2m will fall into each subsequent year.

I agree with Chris insomuch as the tech is superb, both monitoring and labskin (as well as AMBC) and although the share price and IMO comms an absolute ****-show there is huge potential and the current market cap crazy.

The lack of US sales is strange (for monitoring) but given the shocking sentiment I hope he has the good grace to give a detailed trading update for Q1 in April. Cash position wasn’t given in the last one which is poor and maybe has been a catalyst for some to sell. Who knows but I think the benefit of the doubt is not being afforded to GB and more detailed and clear (less ambiguity) is needed.

I’m not saying GB should move aside but I do think he’s marmite and more of the seasoned investors don’t take to him. He can’t control the share price but his job is to create shareholder value and missing targets does not help so set more realistic ones. Does anyone think China Resources will happen any time soon? MOU nearly a year ago and why can’t a senior Chinese MWG rep sign it? Why say it’ll be done by last summer?

No mention of labskin etc so many questions. It all seems a little slapdash and amateur IMO.

Anyway, here’s hoping China Resources signs off ASAP as the longer it drags the lower FY revenue will be.

This is a shocker though. We are below the raise price in April 2019 when we bought Rinocloud. An absolute shocker. I think many distrust Gerry and he needs to start delivering. Great we got some positive news on MWG orders but what about labskin, skintrustclub etc how are they performing from a revenue POV? Why not wait and give a trading update early April re Q1 to include all divisions. Will we ever get any KPIs to measure performance on? Given China going into more restrictions is the JV gonna happen H1 even? Am surprised/disappointed the last update did not include USA, are we struggling to win business there, surely ripe for PD? Sadly I think many PIs are such of the woolly RNSs that pose more questions than answers and see better chances elsewhere. Market cap seems good value here but few buying. Maybe CEO the issue?

I’m not saying that’s the only issue but I certainly know a few who have been put off due to Gerry. I’ve met him and like him but can see why some may want to entrust him. Hopefully things will pivot but we can rebuild, needs to happen soon!

Apologies, if clearly says production orders so that is good news!

I hope you’re right LTbeliever.

It’s confusing snd needs clarifying IMO.

By the way the change in recurring revenue most welcome and the market will love it. $480k/year for maintenance and renewables is great and the ability to add real-time and other added values.

Good to see we have an update and UK trial extended to April but positive equipment has been added to the trial. I wonder if at interim report they will have a breakdown of revenue per division so traditional labskin, skintrustclub, water monitoring etc and introduce KPIs.

Anyway, the explanation was good at the bottom albeit with the currency change a little confusing. In future they should say £5m in orders with £3.5m revenue realised FY22 and circa £1.5m in the following 4 years ($40k per month for 48 months or whatever it is).

It’s £5m in orders not sales. I’m trying to work out if it will all fall this year or with the service agreement there is nearly $2m ($480k over 4 years at $40k a month) to be taken off so £5m in orders but around £3 .5m falls in this year. It’s confusing the change from £ to $.

I think nearly £1.5m falls into next year which is 4 years service etc so around £3.5m this year.